Antigen(s)

DTaP-IPV-HepB/Hib

PCV13

MenB

RV1

MMR

Hib

VV

DTaP-IPV

Tdap

HPV9

Influenza

rZV

Brand name

Infanrix-hexa

Prevenar 13

Bexsero

Rotarix

Priorix

Hiberix

Varivax

Infanrix-IPV

Boostrix

Gardasil 9

Influvac Tetra

Shingrix

Pregnancy

 

 

 

 

 

 

 

 

Tdap

 

Influenza

 

6 weeks

DTaP-IPV-HepB/Hib

PCV13a

 

RV1

 

 

 

 

 

 

 

 

3 months

DTaP-IPV-HepB/Hib

 

MenBb

RV1

 

 

 

 

 

 

 

 

5 months

DTaP-IPV-HepB/Hib

PCV13

MenB

 

 

 

 

 

 

 

 

 

12 months

 

PCV13

MenB

 

MMR

 

 

 

 

 

 

 

15 months

 

 

 

 

MMR

Hib

VV

 

 

 

 

 

4 years

 

 

 

 

 

 

 

DTaP-IPV

 

 

 

 

11 or 12 years

 

 

 

 

 

 

 

 

Tdap

HPV9
(2 doses)

 

 

45 years

 

 

 

 

 

 

 

 

Tdap

 

 

 

65 years

 

 

 

 

 

 

 

 

Tdap

 

Influenza
(annually)

rZV
(2 doses)

Key:

D = diphtheria; T = tetanus; aP = acellular pertussis; IPV = inactivated polio vaccine; HepB = hepatitis B; Hib = Haemophilus influenzae type b; PCV13 = 13-valent pneumococcal conjugate vaccine; RV1 = rotavirus vaccine (monovalent); MenB = meningococcal B vaccine; MMR = measles, mumps and rubella; VV = varicella vaccine; d = adult diphtheria; ap = adult acellular pertussis; HPV9 = human papillomavirus (9 serotypes); rZV = herpes zoster vaccine.

 

a.     For children at high risk of pneumococcal disease, an additional dose of PCV13 is given at age 3 months.

b.     An alternative approved schedule for MenB given at 8 weeks (2 months), 4 months and 12 months is available.

All individuals aged from 5 years are eligible to receive two doses of a COVID-19 vaccine. Additional doses are also available to different groups.